Kruti Joshi, MPH

Esketamine was associated with significantly larger improvements in work productivity loss and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives.

Potential barriers to treatment with esketamine nasal spray include travel distance, insurance, low socioeconomic status, and minority communities.

Acute suicidal ideation or behavior (SIB) that accompanies major depressive disorder (MDD) may produce a substantial economic burden. This study evaluated health care resource utilization and costs of commercially...